SDC1 and Miyoshi myopathy: MPs emerged as a surrogate marker for response in many cancers including MM32,33, our results failed to consider MPs as a marker for disease progression because of absence of significant differences of MPs across different ISS stages, in spite there were significant association between PMPs and CD138 MPs with increased bony lesions, this study adds to this body of research and provides support for the use of MPs as a novel prognostic for response assessment in MM.